Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.

Journal of medical economics - 1 Nov 2017

Saint-Laurent Thibault Catherine, Moorjaney Divya, Ganz Michael L, Sill Bruce, Hede Shalini, Yuan Yong, Gorsh Boris

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Cost-Benefit Analysis
Share to Hepatitis C, Chronic
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyrrolidines

Share to Sofosbuvir

Share to United States

Share to Valine

Source

Identifiers

PMID: 28745536
DOI: 10.1080/13696998.2017.1360313

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.PMID 28745536Read ↗

Re: Saint-Laurent Thibault C, Moorjaney D, Ganz ML, et al. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. J Med Econ 2017;20:692-702.Semantic proximity Read ↗

Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results".Semantic proximity Read ↗

Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.Semantic proximity Read ↗

LP05 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use programSemantic proximity Read ↗

Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.Semantic proximity Read ↗

Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.Semantic proximity Read ↗

Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.Semantic proximity Read ↗

The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.Semantic proximity Read ↗

Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence.Semantic proximity Read ↗

The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.Semantic proximity Read ↗

Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use programSemantic proximity Read ↗

What is (cost) effective in patients with chronic hepatitis C virus infection?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.